BD inks definitive TriPath purchase pact
This article was originally published in The Gray Sheet
Becton Dickinson's purchase of TriPath Imaging under a definitive $350 mil. agreement, announced Sept. 8, is in line with the terms of BD's initial mid-August purchase offer (1"The Gray Sheet" Aug. 21, 2006, p. 3). TriPath's SurePath cervical cancer screening technology and molecular oncology diagnostics will dovetail with BD's flow cytometry systems for the detection of lymphoma and leukemia to advance BD's position in cancer diagnostics, BD says. Combination of the complementary businesses builds on the firms' 2001 collaboration to develop molecular diagnostics for various forms of cancer. BD expects the deal to close by year-end, pending TriPath shareholder approval and antitrust clearance...
You may also be interested in...
Becton Dickinson will gain TriPath Imaging's SurePath liquid-based Pap test and fledgling molecular oncology diagnostics business should its $350 mil. acquisition offer be accepted
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.